149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)

The phase II KEYNOTE-629 (NCT03284424) study evaluated pembro in LA or R/M cSCC. At first interim analysis (IA1) (April 8, 2019), pembro had encouraging antitumor activity in patients (pts) with R/M cSCC, with an objective response rate (ORR) of 34% per RECIST v1.1 and 39% per irRECIST. LA results were unavailable at first IA because accrual was ongoing. Here, we present response per irRECIST in pts with LA or R/M cSCC at IA2. R/M results provide 15 mo of additional follow-up since IA1.